Study investigates Nexium benefits patients with Zollinger-Elliso...( Los Angeles CA - A new clinical study...),Health

Los Angeles, CA - A new clinical study shows that the proton pump inhibitor (PPI) NEXIUM (esomeprazole magnesium) maintained normal gastric (stomach) acid levels in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion (IGH). Results of the 12-month, multicenter study were presented today at the annual Digestive Disease Week (DDW). NEXIUM is indicated for the treatment of GERD and for NSAID-associated gastric ulcers in as-risk patients.

Zollinger-Ellison syndrome (ZES), a rare but serious chronic condition, is characterized by the development of a tumor or tumors that secrete excessive levels of gastrin, a hormone that stimulates acid production by the stomach. ZES is rare, affecting fewer than three out of every million Americans (less than 1,000 people)¹, but it is chronic, difficult to treat, and may be life-threatening. Most people with ZES are prone to recurrent gastric and duodenal ulcers; other symptoms include abdominal pain, diarrhea and increased fat in the stools.

Twenty-one patients received one of several doses of NEXIUM, depending on the degree of their acid output and symptoms at various times throughout the trial. The results showed that at 12 months, NEXIUM 40 mg twice daily controlled basal acid output (AO) in 14 study participant (67 percent), NEXIUM 80 mg twice daily was required to control AO in 4 study participants (19 percent), and NEXIUM 80 mg given three times daily maintained AO in 1 study participant. (Adequate acid output control was defined as <5 mmol/h for patients who had prior gastric-acid-reducing surgery, and as <10 mmol/h for patients who hadn't had the surgery.) Further, 18 of 20 patients whose acid was controlled by day 10 maintained control for the duration of the study. No patients showed evidence of erosive esophagitis or gastric or duodenal (located in the upper region of the small intestine) ulcers at 12 months.

"Zollinger-Ellison syndrome places indivi
'"/>

Contact: David Albaugh
David.Albaugh@astrazeneca.com
302-886-7098
AstraZeneca
22-May-2006

Page: 1 2
Related medicine news :

1. Study, meta-analysis examine factors associated with death from heatstroke
2. Study says COPD testing is not measuring up
3. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
4. Study reveals gaps in vaccine financing for underinsured children
5. Study suggests nonpharmaceutical interventions may be helpful in severe influenza outbreaks
6. Study shows radiofrequency ablation highly effective in treating kidney tumors
7. Study says normal but out-of-control enzyme may be culprit that signals some cells to become cancer
8. Study finds HIV protease inhibitor drugs may adversely affect the scaffolding of the cell nucleus
9. Study outlines how stroke, head injury can increase risk of Alzheimers disease
10. Study identifies new regulator of fat metabolism
11. Study shows Diachrome improves blood sugar control in people with type 2 diabetes